Assessing Response Using ^𝟗𝟗𝐦Tc-MIBI Early after Interstitial Chemotherapy with Carmustine-Loaded Polymers in Glioblastoma Multiforme: Preliminary Results

Table 4

Comparison of the MIBI ratio between gliadel-treated patients with a first diagnosis as opposed to relapsing disease.

Diagnosis	Raw mean (SD)		Least squares adjusted mean (95% CI)
	Baseline	EAS	EAS	Yes versus no
First diagnosis (𝑛=6)	16.22 (4.71)	5.27 (2.20)	5.83 (2.40–9.26)	−1.17 (−5.64–3.30)
Relapsing disease (𝑛=9)	21.20 (13.84)	7.37 (5.10)	7.00 (4.21–9.78)

Baseline: MIBI ratio at baseline; EAS: MIBI ratio early after surgery.